70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups

In an exploratory subgroup analysis of the MINDACT trial, researchers evaluated 8-year distant metastasis-free survival among patients with HR+ HER2, clinical high-risk/genomic low-risk breast cancer who were older than age 50. The findings support the prognostic performance of the 70-gene signature in patients with high-risk features, suggesting that a low 70-gene risk may help identify patients for whom chemotherapy may be avoided.